tetano
Editor, Senior Moderator
Sci Rep
. 2021 Jun 30;11(1):13588.
doi: 10.1038/s41598-021-92323-8.
Increased risk of acute kidney injury in coronavirus disease patients with renin-angiotensin-aldosterone-system blockade use: a systematic review and meta-analysis
Sul A Lee[SUP] 1 2 [/SUP], Robin Park[SUP] 2 [/SUP], Ji Hyun Yang[SUP] 2 [/SUP], In Kyung Min[SUP] 3 [/SUP], Jung Tak Park[SUP] 1 [/SUP], Seung Hyeok Han[SUP] 1 [/SUP], Shin-Wook Kang[SUP] 1 [/SUP], Tae-Hyun Yoo[SUP] 4 [/SUP]
Affiliations
Abstract
Acute kidney injury (AKI) is a severe complication of coronavirus disease (COVID-19) that negatively affects its outcome. Concern had been raised about the potential effect of renin-angiotensin-aldosterone system (RAAS) blockades on renal outcomes in COVID-19 patients. However, the association between RAAS blockade use and incident AKI in COVID-19 patients has not been fully understood. We investigated the association between RAAS blockade exposure and COVID-19-related AKI in hospitalized patients through meta-analysis. Electronic databases were searched up to 24th December 2020. Summary estimates of pooled odds ratio (OR) of COVID-19-related AKI depending on RAAS blockade exposure were obtained through random-effects model. The random-effect meta-analysis on fourteen studies (17,876 patients) showed that RAAS blockade use was significantly associated with increased risk of incident AKI in hospitalized COVID-19 patients (OR 1.68; 95% confidence interval 1.19-2.36). Additional analysis showed that the association of RAAS blockade use on COVID-19-related AKI remains significant even after stratification by drug class and AKI severity. RAAS blockade use is significantly associated with the incident AKI in hospitalized COVID-19 patients. Therefore, careful monitoring of renal complications is recommended for COVID-19 patients with recent RAAS blockade use due to the potential risk of AKI.
. 2021 Jun 30;11(1):13588.
doi: 10.1038/s41598-021-92323-8.
Increased risk of acute kidney injury in coronavirus disease patients with renin-angiotensin-aldosterone-system blockade use: a systematic review and meta-analysis
Sul A Lee[SUP] 1 2 [/SUP], Robin Park[SUP] 2 [/SUP], Ji Hyun Yang[SUP] 2 [/SUP], In Kyung Min[SUP] 3 [/SUP], Jung Tak Park[SUP] 1 [/SUP], Seung Hyeok Han[SUP] 1 [/SUP], Shin-Wook Kang[SUP] 1 [/SUP], Tae-Hyun Yoo[SUP] 4 [/SUP]
Affiliations
- PMID: 34193877
- DOI: 10.1038/s41598-021-92323-8
Abstract
Acute kidney injury (AKI) is a severe complication of coronavirus disease (COVID-19) that negatively affects its outcome. Concern had been raised about the potential effect of renin-angiotensin-aldosterone system (RAAS) blockades on renal outcomes in COVID-19 patients. However, the association between RAAS blockade use and incident AKI in COVID-19 patients has not been fully understood. We investigated the association between RAAS blockade exposure and COVID-19-related AKI in hospitalized patients through meta-analysis. Electronic databases were searched up to 24th December 2020. Summary estimates of pooled odds ratio (OR) of COVID-19-related AKI depending on RAAS blockade exposure were obtained through random-effects model. The random-effect meta-analysis on fourteen studies (17,876 patients) showed that RAAS blockade use was significantly associated with increased risk of incident AKI in hospitalized COVID-19 patients (OR 1.68; 95% confidence interval 1.19-2.36). Additional analysis showed that the association of RAAS blockade use on COVID-19-related AKI remains significant even after stratification by drug class and AKI severity. RAAS blockade use is significantly associated with the incident AKI in hospitalized COVID-19 patients. Therefore, careful monitoring of renal complications is recommended for COVID-19 patients with recent RAAS blockade use due to the potential risk of AKI.